RECURRENT NON SMALL CELL LUNG CANCER
Clinical trials for RECURRENT NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RECURRENT NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug duo targets hard-to-treat lung cancer in early trial
Disease control CompletedThis early-phase study tested a new drug called ONO-7475 combined with the standard targeted therapy osimertinib in 78 people with advanced EGFR-mutant non-small cell lung cancer that could not be treated with radiation. The main goal was to check safety and find the right dose. …
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:53 UTC
-
New drug combo shows promise against lung cancer brain metastases
Disease control CompletedThis study tested two drugs, amivantamab and lazertinib, in 43 adults with a specific type of lung cancer (EGFR-mutant) that had spread to the brain and was getting worse despite previous treatments. The goal was to see if the combination could shrink or control brain tumors. Bot…
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 05:46 UTC